Soleno Therapeutics, Inc. (SLNO) Stock Ticker
SLNO right now
Market factors today
Unlock the full SLNO picture
About Soleno Therapeutics, Inc.
Soleno Therapeutics, Inc. (SLNO) operates as a clinical-stage biopharmaceutical company, specializing in the creation and market introduction of groundbreaking treatments for uncommon illnesses. The cornerstone of its therapeutic pipeline is Diazoxide Choline Controlled-Release, a once-daily oral tablet aimed at addressing Prader-Willi Syndrome, currently progressing through an active Phase III clinical evaluation. Established in 1999, the Redwood City, California-headquartered firm adopted its current name, Soleno Therapeutics, Inc., in May 2017, having previously operated as Capnia, Inc.
SLNO stock facts
| Ticker symbol | SLNO |
| Exchange | NASDAQ Capital Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $2.8B |
| CEO | Anish Bhatnagar |
| Employees | 115 |
| Headquarters | Redwood City, CA, US |
| IPO date | 2014-11-13 |
| Website | soleno.life |
What you can see for SLNO on Tickr
Live SLNO price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the SLNO report.
Rankings
FAQ
What is the ticker symbol for Soleno Therapeutics, Inc.?
The ticker symbol for Soleno Therapeutics, Inc. is SLNO, listed on the NASDAQ Capital Market.
What is SLNO?
Soleno Therapeutics, Inc. (SLNO) operates as a clinical-stage biopharmaceutical company, specializing in the creation and market introduction of groundbreaking treatments for uncommon illnesses. The cornerstone of its therapeutic pipeline is Diazoxide Choline Controlled-Release, a once-daily oral tablet aimed at addressing Prader-Willi Syndrome, currently progressing through an active Phase III…